DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Information source: Novartis
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: HCTZ + Amlodipine (Drug); Valsartan/HCTZ (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Novartis Pharmaceuticals

Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Chair, Affiliation: Novartis Pharmaceuticals

Summary

The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure [MSSBP] >150 mmHg) patients.

Clinical Details

Official title: A 16-Week Double-Blind, Randomized, Multicenter, Force-Titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change in Mean Sitting Systolic Blood Pressure (MSSBP)

Secondary outcome:

Change in Mean Sitting Diastolic Blood Pressure (MSDBP)

Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)

Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)

Change From Baseline in Postprandial Glucose

Change From Baseline in Postprandial Insulin

Change From Baseline in Postprandial Non-Esterified Fatty Acids

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 40 years of age or older

- Moderate or severe high blood pressure defined as systolic blood pressure (the top

number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg

- Central (abdominal) obesity

Exclusion Criteria:

- Systolic blood pressure (the top number) greater than or equal to 180 mmHg and

diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg

- Currently taking more then 3 medications to treat high blood pressure

- Inability to stop all current blood pressure medications if any up to 4 weeks

- History of Type 1 or Type 2 diabetes

- History of stroke, mini-stroke (transient ischemic attack) or heart attack within the

last 6 months

- History of or current diagnosis of congestive heart failure

- History of cancer within the past 5 years with the exception of localized basal cell

carcinoma or squamous cell carcinoma

- Women who are pregnant or nursing

- Alcohol or drug abuse within the last 2 years

Other protocol-defined inclusion/exclusion criteria may apply

Locations and Contacts

Terence T. Hart, MD, Muscle Shoals, Alabama 35662, United States

Westlake Medical Research, Westlake Village, California 91361, United States

Oklahoma Cardiovascular & Hypertension, Oklahoma City, Oklahoma 73132, United States

Northeast Tarrant Internal Medicine Assoc, Euless, Texas 76040, United States

Frandsen Family Medicine, Port Orchard, Washington 98366, United States

Additional Information

Starting date: December 2006
Last updated: February 9, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017